NCT01975441View on ClinicalTrials.gov

Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa

PHASE2CompletedINTERVENTIONAL

Enrollment

182

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

December 31, 2017

Study Completion Date

June 30, 2018

Conditions

Lymphatic Filariasis

Interventions

DRUG

Diethylcarbamazine

Diethylcarbamazine 6mg/kg

DRUG

Albendazole

Albendazole 400mg

DRUG

Ivermectin

Ivermectin 200 mcg/kg

Trial Locations (1)

Unknown

Papua New Guinean Institute for Medical Research, Maprik

All Listed Sponsors

lead

University Hospitals Cleveland Medical Center

OTHER

NCT01975441 - Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa | Biotech Hunter | Biotech Hunter